Oral dapsone was used to treat five patients who presented in the acute inflammatory phase ofocular pemphigoid. The diagnosis was made clinically by identifying cicatricial changes which were in some cases difficult to find. In all cases it was the inflammatory rather than the cicatricial features which responded to treatment. An initial dose of 100 mg/day was effective without toxicity. When Whether or not there was a history of skin lesions all patients were examined by a dermatologist.
Abstract
Oral dapsone was used to treat five patients who presented in the acute inflammatory phase ofocular pemphigoid. The diagnosis was made clinically by identifying cicatricial changes which were in some cases difficult to find. In all cases it was the inflammatory rather than the cicatricial features which responded to treatment. An initial dose of 100 mg/day was effective without toxicity. When 150 mg/day was used patients experienced side effects. A clinical response was obtained after 1-4 weeks and could be maintained on a dose of between 50 mg on alternate days and 100 mg/day. Therapy was withdrawn during remissions which lasted up to 32 weeks but all cases required continuing therapy which has remained effective. Immunopathological examination was carried out on two occasions in all cases and although positive on at least one occasion the results did not correlate with disease activity or treatment. The inflammatory phase of ocular. pemphigoid should be added to the list of diseases responsive to dapsone.
Cicatricial pemphigoid is a disease of unknown aetiology which results in chronic progressive blistering and scarring of mucosal epithelium. The oral mucosa is most commonly affected with the conjunctiva involved in 75% of cases and the skin in 21-30%. ' Conjunctival and skin biopsies and serum samples for immunological assay were taken from each patient while they were without treatment and the disease was active and when the condition was in remission during treatment. Conjunctival biopsies were taken by a snip of upper bulbar conjunctiva elevated with forceps under topical anaesthesia with amethocaine 1% eye drops. Skin snip biopsy was taken from normal skin on the volar surface of the forearm after subcutaneous injection of 1% lignocaine with adrenaline. The specimens were frozen in liquid nitrogen and direct immunofluorescence staining performed with fluorescein-labelled antisera to human IgG, IgA, IgM, and C3. Indirect studies were performed for circulating antibodies to conjunctival epithelium and its basement membrane zone.
Dapsone, therapyfor the acute inflammatory phase ofocular pemphigoid 
Results
The mean age of the three male and two female patients was 60 years (range 40-72 years). Three of the five cases presented with undiagnosed chronic conjunctivitis resistant to treatment. The diagnosis was eventually made clinically when previously overlooked subconjunctival fibrosis and symblepharon were identified (Fig 1) . Selective involvement of the medial or lateral canthus was not present. In the other two patients cicatricial changes were obvious on presentation (Fig 2) allowing more rapid diagnosis.
Though there was cicatrisation in all cases the main presenting problem was chronic conjunctival inflammation with discomfort and pain. Figure 3 shows the inflammed conjunctiva of one patient and Figure 4 the same eye in remission on therapy. While both eyes were involved in every case there was often marked asymmetry. On stopping the drug the latent period before recurrence of the disease varied between patients and for individual patients on different occasions ranging from 1 week to 8 months.
Patient 1 had required treatment for 20 years for primary open angle glaucoma; formerly with topical adrenaline and pilocarpine latterly topical metipiranolol and oral dichlorphenamide. Topical glaucoma therapy was stopped when pemphigoid was diagnosed but the dichlorphenamide was continued.
The acute inflammatory element of ocular pemphigoid responded to the drug in all cases with a clinical response noted between 1-4 weeks after starting dapsone (Table 1 ). The response time varied for different patients but was consistent for each patient on every occasion the drug was recommenced. Some patients had initially received antibiotic and steroid drops but these were discontinued when the inflammation first responded to dapsone and could not account for the improvement in the patients' conjunctival appearance. Although the conjunctival inflammation was controlled by dapsone one case needed supplementary systemic steroid when severe corneal and scleral involvement occurred.
Toxic reactions to dapsone occurred at doses of 100 mg/day or more. There was one case of mild jaundice and one of cyanosis and haemolysis. Both patients were able to continue effective long term therapy at reduced dose.
Dermatological examination identified only one patient with a skin disorder and this was described as psoriaform dermatitis after skin biopsy and is inconsistent with cicatricial pemphigoid. Two patients had oral signs suggestive of pemphigoid.
The immunofluorescent assay results are shown in Table 2 
